This is an unapproved vendor blend of BPC-157, GHK-Cu, and KPV with no dedicated trials. The interest described below is extrapolated from the separate component literature, much of it preclinical. This page describes hypothesized areas of interest, not established benefits, and is not medical advice.
Overview
This blend combines three peptides chosen for complementary recovery-related themes: a repair-associated peptide, a copper skin peptide, and an anti-inflammatory fragment. It is often framed as a "KLOW"-style stack without TB-500. Because no study has tested the combination itself, any appeal rests on the idea that the three components address different parts of a recovery process — a plausible narrative that remains unproven as a unit.
The repair component
BPC-157 is a synthetic peptide studied preclinically for tissue-repair and cytoprotective themes, often in animal models of soft-tissue and gut injury. In this blend it represents the "repair" idea. Importantly, the human evidence for BPC-157 is limited, and its inclusion reflects hypothesis rather than demonstrated clinical benefit.
The skin and collagen component
GHK-Cu is a naturally occurring copper-binding tripeptide investigated in skin, collagen, and wound-related contexts, and it appears in some topical cosmetic research. Within the blend it contributes the skin- and collagen-associated theme. As with the others, this reflects component-level interest rather than validated outcomes from the combined product.
The anti-inflammatory component
KPV is a short C-terminal fragment of the hormone alpha-MSH and has been studied preclinically for anti-inflammatory themes, including in models of gut inflammation. Its role in the blend is to add an inflammation-modulating element. The idea is that reducing inflammatory signaling could complement repair processes, though this synergy has not been demonstrated in the blend.
Evidence and caveats
The central caveat is that combining three peptides does not create a proven therapy:
- There are no trials on this specific blend.
- Each component's own evidence is largely preclinical or early-stage.
- Extrapolating from separate studies to a mixture is a large logical leap.
- It is not an FDA-approved product, and combination behavior is unknown.
Component-level interest is not the same as evidence that the blend helps anyone.